Company: ABBV
Filing Date: 2025-03-24
Form Type: DEF 14A
Source: 0001558370-25-003537
Chunk: 3

Company: AbbVie Inc.
Filing Date: 2025-03-24
Form: DEF 14A
Chunk 3
---
 ​ | ​ | ​ | ​ | ​ | ​ |                                 |
| 2nd place out of 10               |   |   |   |   |   |   |   |   |   | ​ | ​ |                                 |

AbbVie’s peer group above includes:Amgen, Inc; Bristol-Myers Squibb Company; Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline plc; Johnson & Johnson; Merck & Company, Inc; Novartis AG; and Pfizer Inc. TSR measured as of 12/31/24.

4 | 2025 Proxy Statement

| ​ | ​             |
| ​ | PROXY SUMMARY |

Our Governance Highlights Our Board of Directors is committed to strong corporate governance tailored to meet the needs of AbbVie and its stockholders to enhance long-term stockholder value. Each year, AbbVie completes a robust investor engagement program with governance investment teams. Our engagements in 2024 included discussions on (1) AbbVie’s CEO transition, (2) the Board’s leadership changes, including a new Lead Independent Director and all new committee chairs, (3) AbbVie’s processes and disclosures related to its political expenditures and lobbying activities, (4) AbbVie’s executive compensation programs, (5) AbbVie’s actions in response to its 2024 shareholder proposals, including continuing to propose that shareholders eliminate supermajority voting via a management proposal, and (6) AbbVie’s environmental, social, and governance (ESG) strategy and initiatives. AbbVie also engages each year with each of its stockholders who submit proposals for the annual meeting. Each year, the Board reviews feedback from our investor engagements and discusses opportunities to improve AbbVie’s governance practices. The following chart summarizes some of the governance practices that the Board has adopted over the past several years as a result of dialogue with our stockholders:

| ​ | ​                                                       | ​                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| ​ | Topic:                                                  | Actions taken by our Board:                                                                                                                                                                                                                                                                                                                                                                                                                |
| ​ | Stockholder Voting Rights                               | approved a management proposal to eliminate supermajority voting (Item 4) to seek stockholder approval to amend the company’s Amended and Restated Certificate of Incorporation to provide for a simple majority of shares outstanding for all provisions previously subject to a supermajority provision and previously submitted the same proposal from 2018 to 2024 as well as a declassification management proposal from 201